Transient Ischemic Attack Market Size was valued at USD 0.09 Billion in 2023. The Global Transient Ischemic Attack industry is projected to grow from USD 0.12 Billion in 2024 to USD 0.29 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.24% during the forecast period (2024 - 2032).
Transient ischemic stroke is also known as a mini-stroke. It leads to temporary blockage of blood flow to the brain. As it does not cause permanent damage, it is often ignored. The market is mainly driven by factors such as the rising prevalence of ischemia stroke cases, growing geriatric population, and increasing healthcare expenditure. However, the high cost of surgical procedures for the treatment of ischemic is likely to hinder the market growth.
The transient ischemic attack market is expected to exhibit exponential growth during the forecast period which is driven by all-rounder characteristics of the transient ischemic attack, increasing prevalence of chronic diseases such as cardiovascular diseases and cancer, and increase in the treatment of chronic diseases for the elderly population. It has been identified as one of the fastest emerging industries owing to the changing dynamics of the legal and regulatory framework and the intense competitive rivalry among an excess of public companies.
As per the survey carried out by American Heart Association Report 2015, more than 17.9 million deaths were recorded in the US due to cardiovascular disorder, and the death rate is expected to grow to more than 23.6 Million by 2030. Besides, increasing healthcare expenditure has fueled the growth of the market. However, the growth of the market is restrained by the side effects of drugs for strokes and strict regulations for manufacturing medical devices for the treatment of strokes.
The transient ischemic attack has been segmented into diagnosis, treatment, age group, and end user. Based on the diagnosis, the market has been divided into imaging techniques and others. The imaging technique is further sub-segmented into computed tomography (CT) scan, carotid duplex scanning, magnetic resonance imaging, and echocardiography. The imaging technique segment accounted for a market value of USD 1004.4 Million in 2016. Based on treatment, the market has been segregated into surgery and drugs. The drugs segment is further sub-segmented into antithrombotic agents, antiplatelets, clopidogrel, aspirin, heparins, enoxaparin, dalteparin, fibrinolytic, and tenecteplase. By age groups, the market is further classified as 0–18 years, 19–40 years (Millennial), 41–60 years, and 60+ years. Based on end-user, the transient ischemic attack market has been bifurcated into hospitals & clinics, diagnostic centers, and research laboratories.
The prominent players in the transient ischemic attack market are:
The transient ischemic attack market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is estimated to dominate the transient ischemic attack market during the forecast period. This is attributed due to the well-developed technology, rising healthcare expenditure, and the presence of the leading players in the market. People in this region are very health conscious, which has led to increasing healthcare expenditure in this region.
Europe accounted for the second-largest market for transient ischemic attack. Rising investment in research & development, well-developed healthcare infrastructure, and increasing healthcare funds are some of the factors responsible for boosting the growth of the market in this region.
Asia-Pacific is projected to be the fastest-growing market due to the rising aging population, increasing healthcare expenditure, and the rising prevalence of cardiac disorders. In addition to this, improving healthcare facilities and rising economic growth is positively impacting the market growth in this region. Japan held the most significant market share of 32.97 % in 2016.
The market in the Middle East & Africa is expected to witness steady growth due to increasing investments in research & development, well-developed infrastructure, and advancement in technology.
Key Updates
Available Additional Customizations
Intended Audience
| Report Attribute/Metric | Details |
| Market Size 2030 | Â USD 0.29 Billion 2032 |
| Compound Annual Growth Rate (CAGR) | 9.34% 2032 |
| Base Year | 2021 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018 - 2021 |
| Market Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product, technology, application, and end-users. |
| Geographies Covered | Americas, Europe, Asia Pacific and the Middle East and Africa |
| Countries Covered | China, Japan, India, Australia, South Korea, Australia, Rest of Asia-Pacific |
| Key Companies Profiled | Koninklijke Philips NV (Netherlands), Stryker Corporation (US), Johnson & Johnson Services Inc (US), Boston Scientific Corporation (US), Sanofi (France), Bayer AG (Germany), Pfizer Inc (US), Siemens AG (US), F. Hoffmann-La Roche AG (Switzerland), GE Healthcare (UK), Penumbra Inc (California), Medtronic PLC (Ireland), Abbott Laboratories (US), Merck & Co., Inc (US), and Boehringer Ingelheim GmbH (Germany). |
| Key Market Opportunities | Key market opportunities for the Transient Ischemic Attack market include the development of advanced diagnostic tools, innovative treatment options, and personalized medicine approaches to improve early detection and patient outcomes. |
| Key Market Dynamics | Â The key market dynamics for the transient ischemic attack (TIA) market include increasing incidence rates, advances in diagnostic and therapeutic technologies, growing awareness and early intervention, and substantial investment in research and development. |
Transient Ischemic Attack Market Highlights:
Frequently Asked Questions (FAQ) :
Transient ischemic attack market projected to grow at approximately 9.24% CAGR during the assessment period (2024-2032).
The valuation of the global transient ischemic attack market is estimated to increase to USD 0.29 Billion by the end of 2032.
Rising need for better treatment due to the increasing prevalence of neurological disorders and increasing R&D investments in biotechnology and pharmaceutical sectors are major tailwinds pushing the growth of the global transient ischemic attack market.
North America holds the largest share in the global transient ischemic attack market, followed by Europe and the Asia Pacific, respectively.
EnteroMedics Inc. (U.S.), ElectroCore Medical LLC (U.S.), LivaNova PLC (U.K), Cyberonics, Inc. (US), NeuroMetrix, Inc.(U.S.), Boston Scientific Corporation (US), Inspire Medical Systems Inc.(U.S.), Electrical Geodesics Inc. (U.S.), ImThera Medical (U.S.), Nihon Kohden Corporation (Japan), Esaote (Italy), Masimo Corporation (U.S.), and Hologic (U.S.), are some of the top players operating in the global transient ischemic attack market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
